Found: 16
Select item for more details and to access through your institution.
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 12, p. 882, doi. 10.1016/j.clml.2023.08.012
- By:
- Publication type:
- Article
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. 690, doi. 10.1016/j.clml.2022.04.025
- By:
- Publication type:
- Article
OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02098-X
- By:
- Publication type:
- Article
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 701, doi. 10.1016/j.clml.2021.05.017
- By:
- Publication type:
- Article
MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
- By:
- Publication type:
- Article
Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
- By:
- Publication type:
- Article
Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
- By:
- Publication type:
- Article
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e85, doi. 10.1016/j.clml.2017.03.153
- By:
- Publication type:
- Article
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
- Published in:
- Cancer Reports, 2022, v. 5, n. 11, p. 1, doi. 10.1002/cnr2.1603
- By:
- Publication type:
- Article
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
- By:
- Publication type:
- Article
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
- By:
- Publication type:
- Article
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
- By:
- Publication type:
- Article
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.
- Published in:
- Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0
- By:
- Publication type:
- Article